Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 5, 2013 Phillip Broadwith	Roche to release Tamiflu trial data Swiss pharma company Roche has finally agreed to give independent researchers access to data on all 74 clinical trials it ran on the antiviral influenza drug Tamiflu (oseltamivir).
Chemistry World January 7, 2014 Angeli Mehta	Flu drug stockpile may be worthless The case for spending hundreds of millions of pounds stockpiling antivirals for use in a flu pandemic is based on 'judgement rather than on evidence of their effectiveness', according to a parliamentary committee.
Chemistry World June 26, 2012 Sarah Houlton	Roche rapped for side-effect reporting failure Roche has been rapped by the European Medicines Agency for failing to report a large number of potential drug side-effects. The UK's Medicines and Healthcare products Regulatory Agency identified deficiencies in the company's medicine safety reporting system.
Information Today July 9, 2015	The BMJ Requires Patient-Level Data for Publication The BMJ is now applying its data-sharing policy to all clinical trials.
Chemistry World October 17, 2012 Maria Burke	GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency.
Chemistry World February 7, 2013 Maria Burke	GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public.
Chemistry World January 3, 2013 Sarah Houlton	2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012.
Chemistry World May 8, 2013 Phillip Broadwith	Clinical trial data release blocked by companies Two pharmaceutical companies have been granted injunctions to prevent the European Medicines Agency from releasing clinical trial data about their drugs.
Pharmaceutical Executive November 1, 2014	EMA -- a Pioneer Permanently At Bay Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients.
Chemistry World October 8, 2014 Phillip Broadwith	EMA finalizes trial transparency rules The European Medicines Agency has finalized its policy for sharing data from clinical trials.
Chemistry World September 30, 2014	Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data.
The Motley Fool October 17, 2006 Brian Lawler	Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at.
The Motley Fool October 17, 2005 Brian Gorman	Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine.
Managed Care November 2002	Flu season: Most HMO formularies cover Tamiflu, Relenza As the influenza season approaches, managed care patient access to Tamiflu (oseltamivir) from Roche Laboratories and Relenza (zanamivir) from GlaxoSmithKline, the two medications indicated for influenza, looks relatively open.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
Chemistry World April 2, 2015 Emma Stoye	Novartis accused of 'derailing' trials for cheap eye disease drug The British Medical Journal has accused pharmaceutical giant Novartis of deliberately hindering research into the use of anticancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration.
Chemistry World July 24, 2009 Matt Wilkinson	Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared.
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
The Motley Fool March 16, 2006 Rich Duprey	Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about.
Pharmaceutical Executive March 1, 2014 Jill Wechsler	Data disclosure, integrity challenge pharma Transparency initiatives are multiplying, affecting research, marketing and compliance.
The Motley Fool May 28, 2009 Brian Orelli	How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now?
The Motley Fool February 4, 2010 Brian Orelli	Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last?
Bio-IT World April 2006 Mark D. Uehling	Debating Clinical Registries and Databases The pharmaceutical industry has been forced by medical journal editors and Congress to make public more data about clinical trials. Registries are here, most people are used to them, and they're not going away. But can the industry do registries and databases better?
The Motley Fool June 3, 2011 Brian Orelli	Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up.
Chemistry World August 6, 2013 Phillip Broadwith	Antiviral patents released by Roche A five-year agreement between Roche and Unitaid's Medicines Patent Pool will make more antiviral drugs available at knock-down prices in developing countries.
Chemistry World October 29, 2014 Phillip Broadwith	CHF3bn redevelopment for Roche's Basel site Swiss pharma major Roche plans to spend CHF3 billion ( 2 billion pounds) over the next 10 years on redeveloping its headquarters in Basel.
Chemistry World December 22, 2010 Sarah Houlton	Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US.
The Motley Fool April 27, 2009 Brian Orelli	A Capitalist Pig's View of Swine Flu So you want to make money from the swine flu? Here's how to do so.
The Motley Fool October 30, 2006 Brian Lawler	InterMune Plays "Let's Make a Deal" The biopharmaceutical 's deal with Roche could mean stiff competition for rival Vertex. Investors, take note.
Chemistry World February 26, 2014 Ned Stafford	Roche disputes unethical East German trial claims Clinical trials in the 1980s, performed in former communist East Germany by global pharmaceutical giant Hoffmann-La Roche, adhered to international standards and did not violate East German laws, according to a report issued by the company after a six month internal investigation.
Chemistry World July 3, 2014 Andy Extance	EMA wrangles restrain trial data progress Tempers are being tested as the pharmaceutical industry's journey towards transparency on clinical trial data enters a critical phase.
The Motley Fool October 17, 2008 Brian Orelli	Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results.
The Motley Fool January 28, 2009 Brian Orelli	Worth Every Penny People still need to take their antiviral medication even if the purse strings are tight, and that fact has led Gilead Sciences to putting together another great quarter.
The Motley Fool June 12, 2009 Brian Orelli	Be Careful What You Wish For Do you have the stomach to profit from swine flu?
BusinessWeek October 31, 2005 Gene G. Marcial	Why Biocryst Has Wings Shares of the pharmaceutical are on fire, soaring from $4.39 a share in early April to $15 on Oct. 19.
Information Today May 13, 2013 Marydee Ojala	Cochrane's New Look At this year's Medical Libraries Association annual conference, held May 3-7, 2013, in Boston, several sessions centered on new and forthcoming developments with The Cochrane Collaboration.
Information Today October 22, 2013	Wiley and The Cochrane Collaboration Develop Cochrane Learning Wiley and The Cochrane Collaboration recently launched Cochrane Learning, a professional development resource for the healthcare industry.
Wired December 2006 Erika Check	The Treasure of Mumbai In the pharmaceutical industry, Indian drugmaker Cipla is a pirate operation. To the developing world, it's a vital medicine chest. And now its cheap pills are coming to a pharmacy near you.
Chemistry World April 9, 2008 Richard Van Noorden	The shortest recipe for Tamiflu US chemists have published the shortest synthesis to date of oseltamivir (Tamiflu), the anti-influenza drug which is also used to treat bird flu.
Pharmaceutical Executive November 1, 2013 Jill Wechsler	Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.
The Motley Fool March 30, 2006 David Compton	Glaxo's New Flu-Fighting Ammo The FDA certifies the drugmaker's Relenza for defense as well as offense. For investors seeking to give their portfolios a shot in the arm, now might be the time to take a closer look at Glaxo.
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
The Motley Fool July 20, 2007 Andrew R. Vaino	BioCryst Is for the Birds Fears of bird flu resurrected a drug for this small pharma, and it has some other promising compounds in the pipeline. Based only on its pipeline size, BioCryst should be valued higher. But make no mistake: This is a risky stock.
The Motley Fool July 22, 2009 Brian Orelli	Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.
BusinessWeek December 13, 2004 Bruce Einhorn	Go East, Big Pharma Drugmakers are expanding in China, but patents are still a worry.
The Motley Fool December 18, 2009 Brian Orelli	Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.
Pharmaceutical Executive January 1, 2006 Jill Wechsler	Washington Report: PDUFA Blues The Prescription Drug User Fee Act is up for reauthorization. Let the games begin.
The Motley Fool June 11, 2010 Claire Stephanic	Motley Fool Wire: Top 3 Stories Selected stories from around the Web that feature BP, McDonald's, and swine flu experts' ties to big pharma.
AskMen.com	Drug-Resistant Swine Flu Surfaces Health officials have confirmed a case of swine flu that is resistant to Tamiflu, the leading pharmaceutical weapon against the new virus.